Comparative Pharmacology
Head-to-head clinical analysis: IMPAVIDO versus LAMPIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPAVIDO versus LAMPIT.
IMPAVIDO vs LAMPIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miltefosine, the active ingredient in IMPAVIDO, is an alkylphosphocholine with antileishmanial activity. It interacts with cell membrane phospholipids, inhibits cytochrome c oxidase, and induces apoptosis-like cell death in Leishmania parasites. It also modulates host immune responses.
Inhibits the enzyme G6PD (glucose-6-phosphate dehydrogenase) in Trypanosoma cruzi, leading to oxidative stress and parasite death.
60 mg/kg body weight per day (2.5 mg/kg per hour) by intravenous infusion over 6 hours, up to a maximum of 150 mg/day, for 21 days.
Nifurtimox (Lampit) for Chagas disease: adult dose 8-10 mg/kg/day orally in 3 divided doses for 90 days. For Chagas disease in children: 15-20 mg/kg/day orally in 3 divided doses for 90 days.
None Documented
None Documented
Terminal elimination half-life is approximately 16-21 days in adults; may be longer in severe hepatic impairment.
Terminal elimination half-life is approximately 20 hours. In hepatic impairment, half-life may be prolonged by up to 2-fold.
Primarily renal (over 90% as unchanged drug); fecal excretion is minimal (<5%).
Renal excretion of unchanged drug accounts for 10% of the dose; biliary/fecal excretion accounts for approximately 90%, mainly as metabolites.
Category C
Category C
Antiprotozoal
Antiprotozoal